Jazz Presents Overall Survival & Longer Data From Trial Of Zanidatamab In Biliary Tract Cancer

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) announced long-term follow-up results, including the first-ever overall survival or OS findings, from the Phase 2b HERIZON-BTC-01 clinical trial of zanidatamab in previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer or BTC.

The company noted that Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors.

The median duration of response (DoR), one of the trial's key secondary endpoints, increased by approximately 2 months to 14.9 months, compared to the previously reported findings. In the data cut, zanidatamab demonstrated a median estimated OS, another secondary endpoint, of 15.5 months in all patients with HER2+ BTC, 18.1 months in patients with IHC 3+ tumors, and 5.2 months in patients with IHC 2+ tumors. Results highlight the clinically meaningful benefits of sustained and durable responses with continued treatment with zanidatamab.

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.